Overview

Mifepristone for Treatment of Uterine Fibroids

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to estimate the efficacy and safety of the daily administration of mifepristone 5 mg versus 10 mg for three months for the treatment of uterine fibroids. The hypothesis of the study is that both mifepristone doses reduce the volume of the myoma in about 40% after 3 months of treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mediterranea Medica S. L.
Treatments:
Mifepristone